Regression of oxidative stress by targeting eNOS and Nrf2/ARE signaling: A guided drug target for cardiovascular diseases

Current Topics in Medicinal Chemistry

Volumn 15, Issue 9, 2015, Pages 857-871

  Ramprasath, Tharmarajan ^a   Vasudevan, Varadaraj ^a   Sasikumar, Sundaresan ^a   Mohamed Puhari, Shanavas Syed ^a   Saso, Luciano ^b   Selvam, Govindan Sadasivam ^a  

^a MADURAI KAMARAJ UNIVERSITY   (India)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CVD; Endothelial dysfunction; eNOS; Nitric oxide; Nrf2 ARE; Phase II antioxidant enzymes

Indexed keywords

APIGENIN; ASCORBIC ACID; BARDOXOLONE METHYL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BRUSATOL; CARNOSIC ACID; CURCUMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPICATECHIN; EPIGALLOCATECHIN GALLATE; FISETIN; GLUTATHIONE PEROXIDASE; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LOW DENSITY LIPOPROTEIN; LUTEOLIN; MASLINIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NARINGENIN; OCHRATOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PICEATANNOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; SCHIZANDRIN B; SULFORAPHANE; TANSHINONE IIA; THIOCTIC ACID; TRANSCRIPTION FACTOR NRF2; TRIGONELLINE; ANTIOXIDANT; NFE2L2 PROTEIN, HUMAN; NITRIC OXIDE; NOS3 PROTEIN, HUMAN;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; GENETIC POLYMORPHISM; HEART CONTRACTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

ANIMALS; ANTIOXIDANT RESPONSE ELEMENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; ENDOTHELIUM, VASCULAR; HUMANS; NF-E2-RELATED FACTOR 2; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84928879823     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150220114417     Document Type: Article

References (141)

1. Schrier, R.W.; Abdallah, J.G.; Weinberger, H.H.; Abraham, W.T., Therapy of heart failure. Kidney Int., 2000, 57, (4), 1418-1425
2. Ashrafian, H.; Frenneaux, M.P.; Opie, L.H., Metabolic mechanisms in heart failure. Circulation, 2007, 116, (4), 434-448
3. Mosterd, A.; Hoes, A.W., Clinical epidemiology of heart failure. Heart, 2007, 93, (9), 1137-1146
4. McMurray, J.J.; Adamopoulos, S.; Anker, S.D.; Auricchio, A.; Bohm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gomez-Sanchez, M.A.; Jaarsma, T.; Kober, L.; Lip, G.Y.; Maggioni, A.P.; Parkhomenko, A.; Pieske, B.M.; Popescu, B.A.; Ronnevik, P.K.; Rutten, F.H.; Schwitter, J.; Seferovic, P.; Stepinska, J.; Trindade, P.T.; Voors, A.A.; Zannad, F.; Zeiher, A., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Euro. heart j., 2012, 33, (14), 1787-1847
5. Parajuli, N.; Ramprasath, T.; Patel, V.B.; Wang, W.; Putko, B.; Mori, J.; Oudit, G.Y., Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases1. Canadian J. Physio.Pharma., 2014, 92, 1-8
6. Harrison, D.; Griendling, K.K.; Landmesser, U.; Hornig, B.; Drexler, H., Role of oxidative stress in atherosclerosis. Am. J. Cardiol., 2003, 91, (3A), 7A-11A
7. Lerman, A.; Zeiher, A.M., Endothelial function: cardiac events. Circulation, 2005, 111, (3), 363-368
8. Li, J.; Ichikawa, T.; Janicki, J.S.; Cui, T., Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin. Ther. Targets, 2009, 13, (7), 785-794
9. Ramprasath, T.; Kumar, P.H.; Puhari, S.S.; Murugan, P.S.; Vasudevan, V.; Selvam, G.S., L-Arginine ameliorates cardiac left ventricular oxidative stress by upregulating eNOS and Nrf2 target genes in alloxan-induced hyperglycemic rats. Biochem. Biophys. Res. Commun., 2012, 428, (3), 389-394
10. Ramprasath, T.; Senthamizharasi, M.; Vasudevan, V.; Sasikumar, S.; Yuvaraj, S.; Selvam, G.S., Naringenin confers protection against oxidative stress through upregulation of Nrf2 target genes in cardiomyoblast cells. J. Physiol.Biochem., 2014, 70, (2), 407-415
11. Carrillo-Sepulveda, M.A.; Matsumoto, T.; Nunes, K.P.; Webb, R.C., Therapeutic implications of peptide interactions with Gprotein- coupled receptors in diabetic vasculopathy. Acta. Physiol. (Oxf), 2014, 211, (1), 20-35
12. Muniyappa, R.; Sowers, J.R., Role of insulin resistance in endothelial dysfunction. Reviews in endocrine & metabolic disorders, 2013, 14, (1), 5-12
13. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A.M., Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999, 399, (6736), 601-605
14. Shen, Y.; Ward, N.C.; Hodgson, J.M.; Puddey, I.B.; Wang, Y.; Zhang, D.; Maghzal, G.J.; Stocker, R.; Croft, K.D., Dietary quercetin attenuates oxidant-induced endothelial dysfunction and atherosclerosis in apolipoprotein E knockout mice fed a high-fat diet: a critical role for heme oxygenase-1. Free radical biology & medicine, 2013, 65, 908-915
15. Stryer, L. Biochemistry. 4 ed. W.H. Freeman and Company, 1995
16. Hanafy, K.A.; Krumenacker, J.S.; Murad, F., NO, nitrotyrosine, and cyclic GMP in signal transduction. Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res., 2001, 7, (4), 801-819
17. Forstermann, U.; Sessa, W.C., Nitric oxide synthases: regulation and function. European heart journal, 2012, 33, (7), 829-837, 837a-837d
18. Rochette, L.; Lorin, J.; Zeller, M.; Guilland, J.C.; Lorgis, L.; Cottin, Y.; Vergely, C., Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol. Therapeut., 2013, 140, (3), 239-257
19. Calabrese, V.; Boyd-Kimball, D.; Scapagnini, G.; Butterfield, D.A., Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In vivo, 2004, 18, (3), 245-267
20. Turko, I.V.; Marcondes, S.; Murad, F., Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoAtransferase. Am. J. Physiol. Heart Circ. Physiol., 2001, 281, (6), H2289-2294
21. Braam, B.; Verhaar, M.C., Understanding eNOS for pharmacological modulation of endothelial function: a translational view. Curr. Pharm. Des., 2007, 13, (17), 1727-1740
22. Cai, H., NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circulation Res., 2005, 96, (8), 818-822
23. Schmidt, T.S.; Alp, N.J., Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin. Sci. (Lond)., 2007, 113, (2), 47-63
24. Sima, A.V.; Stancu, C.S.; Simionescu, M., Vascular endothelium in atherosclerosis. Cell and Tissue Res., 2009, 335, (1), 191-203
25. Campbell, D.L.; Stamler, J.S.; Strauss, H.C., Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J.gen. physio., 1996, 108, (4), 277-293
26. Khan, S.A.; Lee, K.; Minhas, K.M.; Gonzalez, D.R.; Raju, S.V.; Tejani, A.D.; Li, D.; Berkowitz, D.E.; Hare, J.M., Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc. Natl. Acad. Sci. U S A., 2004, 101, (45), 15944-15948
27. Hare, J.M., Nitric oxide and excitation-contraction coupling. J. Mol. Cell Cardiol., 2003, 35, (7), 719-729
28. Barouch, L.A.; Harrison, R.W.; Skaf, M.W.; Rosas, G.O.; Cappola, T.P.; Kobeissi, Z.A.; Hobai, I.A.; Lemmon, C.A.; Burnett, A.L.; O'Rourke, B.; Rodriguez, E.R.; Huang, P.L.; Lima, J.A.; Berkowitz, D.E.; Hare, J.M., Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature, 2002, 416, (6878), 337-339
29. Han, X.; Kubota, I.; Feron, O.; Opel, D.J.; Arstall, M.A.; Zhao, Y.Y.; Huang, P.; Fishman, M.C.; Michel, T.; Kelly, R.A., Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA, 1998, 95, (11), 6510-6515
30. Wang, H.; Kohr, M.J.; Wheeler, D.G.; Ziolo, M.T., Endothelial nitric oxide synthase decreases beta-adrenergic responsiveness via inhibition of the L-type Ca2+ current. Am. J. Physio. Heart Circu. Physio., 2008, 294, (3), H1473-1480
31. Ziolo, M.T.; Kohr, M.J.; Wang, H., Nitric oxide signaling and the regulation of myocardial function. J. Mol. Cell Cardiol., 2008, 45, (5), 625-632
32. Shah, A.M.; MacCarthy, P.A., Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol. Therapeutics, 2000, 86, (1), 49-86
33. Rastaldo, R.; Pagliaro, P.; Cappello, S.; Penna, C.; Mancardi, D.; Westerhof, N.; Losano, G., Nitric oxide and cardiac function. Life sci., 2007, 81, (10), 779-793
34. Zhang, P.; Xu, X.; Hu, X.; van Deel, E.D.; Zhu, G.; Chen, Y., Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ. Res., 2007, 100, (7), 1089-1098
35. Mungrue, I.N.; Gros, R.; You, X.; Pirani, A.; Azad, A.; Csont, T.; Schulz, R.; Butany, J.; Stewart, D.J.; Husain, M., Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J. Clin. Invest., 2002, 109, (6), 735-743
36. Umar, S.; van der Laarse, A., Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol. cell. biochem., 2010, 333, (1-2), 191-201
37. Wu, B.J.; Kathir, K.; Witting, P.K.; Beck, K.; Choy, K.; Li, C.; Croft, K.D.; Mori, T.A.; Tanous, D.; Adams, M.R.; Lau, A.K.; Stocker, R., Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J. exper. med., 2006, 203, (4), 1117-1127
38. Pacher, P.; Beckman, J.S.; Liaudet, L., Nitric oxide and peroxynitrite in health and disease. Physiol. rev., 2007, 87, (1), 315-424
39. Rathaus, M.; Bernheim, J., Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension. Nephrol. Dialysis, Transplantation: Official Pub. Eur. Dialysis Transplant Association - Eur. Renal Association, 2002, 17, (2), 216-221
40. Russo, G.; Leopold, J.A.; Loscalzo, J., Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascular pharmacology, 2002, 38, (5), 259-269
41. Jones, S.P.; Bolli, R., The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell Cardiol., 2006, 40, (1), 16-23
42. Boon, R.A.; Horrevoets, A.J., Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie, 2009, 29, (1), 39-40, 41-33
43. Heo, K.S.; Fujiwara, K.; Abe, J., Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. Circulation J.: Official J. Jpn. Circulation Soc., 2011, 75, (12), 2722-2730
44. Harrison, D.G.; Widder, J.; Grumbach, I.; Chen, W.; Weber, M.; Searles, C., Endothelial mechanotransduction, nitric oxide and vascular inflammation. J. Intern. Med., 2006, 259, (4), 351-363
45. Fleming, I.; Fisslthaler, B.; Dimmeler, S.; Kemp, B.E.; Busse, R., Phosphorylation of Thr(495) regulates Ca(2+)/calmodulindependent endothelial nitric oxide synthase activity. Circulation research, 2001, 88, (11), E68-75
46. Li, C.; Ruan, L.; Sood, S.G.; Papapetropoulos, A.; Fulton, D.; Venema, R.C., Role of eNOS phosphorylation at Ser-116 in regulation of eNOS activity in endothelial cells. Vascular pharmacology, 2007, 47, (5-6), 257-264
47. Taylor, S.Y.; Dixon, H.M.; Yoganayagam, S.; Price, N.; Lang, D., Folic acid modulates eNOS activity via effects on posttranslational modifications and protein-protein interactions. Eur. J. Pharmacol., 2013, 714, (1-3), 193-201
48. Hambrecht, R.; Adams, V.; Erbs, S.; Linke, A.; Krankel, N.; Shu, Y.; Baither, Y.; Gielen, S.; Thiele, H.; Gummert, J.F.; Mohr, F.W.; Schuler, G., Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation, 2003, 107, (25), 3152-3158
49. Ramprasath, T.; Selvam, G.S., Potential impact of genetic variants in Nrf2 regulated antioxidant genes and risk prediction of diabetes and associated cardiac complications. Curr. med. chem., 2013, 20, (37), 4680-4693
50. Nguyen, T.; Nioi, P.; Pickett, C.B., The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. biol. chem., 2009, 284, (20), 13291-13295
51. Chen, J.; Zhang, Z.; Cai, L., Diabetic cardiomyopathy and its prevention by nrf2: current status. Diabetes Metab. J., 2014, 38, (5), 337-345
52. Motohashi, H.; Yamamoto, M., Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med., 2004, 10, (11), 549-557
53. Napoli, C.; Pinto, A.; Cirino, G., Pharmacological modulation, preclinical studies, and new clinical features of myocardial ischemic preconditioning. Pharmacology & therapeutics, 2000, 88, (3), 311-331
54. Xu, B.; Zhang, J.; Strom, J.; Lee, S.; Chen, Q.M., Myocardial ischemic reperfusion induces de novo Nrf2 protein translation. Biochimica et biophysica acta., 2014, 1842, (9), 1638-1647
55. Venugopal, R.; Jaiswal, A.K., Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element- mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. USA, 1996, 93, (25), 14960-14965
56. Keum, Y.S.; Owuor, E.D.; Kim, B.R.; Hu, R.; Kong, A.N., Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharmaceutical research, 2003, 20, (9), 1351-1356
57. Braun, S.; Hanselmann, C.; Gassmann, M.G.; auf dem Keller, U.; Born-Berclaz, C.; Chan, K.; Kan, Y.W.; Werner, S., Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol., 2002, 22, (15), 5492-5505
58. Chen, X.L.; Dodd, G.; Thomas, S.; Zhang, X.; Wasserman, M.A.; Rovin, B.H.; Kunsch, C., Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, (5), H1862-1870
59. Arisawa, T.; Tahara, T.; Shibata, T.; Nagasaka, M.; Nakamura, M.; Kamiya, Y.; Fujita, H.; Hasegawa, S.; Takagi, T.; Wang, F.Y.; Hirata, I.; Nakano, H., The relationship between Helicobacter pylori infection and promoter polymorphism of the Nrf2 gene in chronic gastritis. Int. J. Mol. Med., 2007, 19, (1), 143-148
60. Dai, G.; Vaughn, S.; Zhang, Y.; Wang, E.T.; Garcia-Cardena, G.; Gimbrone, M.A., Jr., Biomechanical forces in atherosclerosisresistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2. Circulation research, 2007, 101, (7), 723-733
61. Kang, K.W.; Choi, S.H.; Kim, S.G., Peroxynitrite activates NF-E2- related factor 2/antioxidant response element through the pathway of phosphatidylinositol 3-kinase: the role of nitric oxide synthase in rat glutathione S-transferase A2 induction. Nitric Oxide: Biol. Chem./Official J. Nitric Oxide Soc., 2002, 7, (4), 244-253
62. Buckley, B.J.; Marshall, Z.M.; Whorton, A.R., Nitric oxide stimulates Nrf2 nuclear translocation in vascular endothelium. Biochem. Biophys. Res. Commun., 2003, 307, (4), 973-979
63. Abbas, K.; Breton, J.; Planson, A.G.; Bouton, C.; Bignon, J.; Seguin, C.; Riquier, S.; Toledano, M.B.; Drapier, J.C., Nitric oxide activates an Nrf2/sulfiredoxin antioxidant pathway in macrophages. Free Radical Biol. Med., 2011, 51, (1), 107-114
64. Dhakshinamoorthy, S.; Porter, A.G., Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. J. Biol. Chem., 2004, 279, (19), 20096-20107
65. Ishikawa, K.; Navab, M.; Leitinger, N.; Fogelman, A.M.; Lusis, A.J., Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL. J. Clin. Invest., 1997, 100, (5), 1209-1216
66. Pae, H.O.; Oh, G.S.; Lee, B.S.; Rim, J.S.; Kim, Y.M.; Chung, H.T., 3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells. Atherosclerosis, 2006, 187, (2), 274-284
67. Liu, X.M.; Peyton, K.J.; Ensenat, D.; Wang, H.; Hannink, M.; Alam, J.; Durante, W., Nitric oxide stimulates heme oxygenase-1 gene transcription via the Nrf2/ARE complex to promote vascular smooth muscle cell survival. Cardiovasc. Res., 2007, 75, (2), 381-389
68. Bea, F.; Hudson, F.N.; Chait, A.; Kavanagh, T.J.; Rosenfeld, M.E., Induction of glutathione synthesis in macrophages by oxidized lowdensity lipoproteins is mediated by consensus antioxidant response elements. Circulation Res., 2003, 92, (4), 386-393
69. Subbanagounder, G.; Leitinger, N.; Schwenke, D.C.; Wong, J.W.; Lee, H.; Rizza, C.; Watson, A.D.; Faull, K.F.; Fogelman, A.M.; Berliner, J.A., Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arte--‐ rioscler Thromb. Vasc. Biol., 2000, 20, (10), 2248-2254
70. Siow, R.C.; Sato, H.; Mann, G.E., Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide? Cardiovascular research, 1999, 41, (2), 385-394
71. Yachie, A.; Niida, Y.; Wada, T.; Igarashi, N.; Kaneda, H.; Toma, T.; Ohta, K.; Kasahara, Y.; Koizumi, S., Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J. Clin. Inves., 1999, 103, (1), 129-135
72. Kawashima, A.; Oda, Y.; Yachie, A.; Koizumi, S.; Nakanishi, I., Heme oxygenase-1 deficiency: the first autopsy case. Human Pathol., 2002, 33, (1), 125-130
73. Anwar, A.A.; Li, F.Y.; Leake, D.S.; Ishii, T.; Mann, G.E.; Siow, R.C., Induction of heme oxygenase 1 by moderately oxidized lowdensity lipoproteins in human vascular smooth muscle cells: role of mitogen-activated protein kinases and Nrf2. Free Radical Biol. Med., 2005, 39, (2), 227-236
74. Hosoya, T.; Maruyama, A.; Kang, M.I.; Kawatani, Y.; Shibata, T.; Uchida, K.; Warabi, E.; Noguchi, N.; Itoh, K.; Yamamoto, M., Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J. Biol. Chem., 2005, 280, (29), 27244-27250
75. Warabi, E.; Takabe, W.; Minami, T.; Inoue, K.; Itoh, K.; Yamamoto, M.; Ishii, T.; Kodama, T.; Noguchi, N., Shear stress stabilizes NF-E2-related factor 2 and induces antioxidant genes in endothelial cells: role of reactive oxygen/nitrogen species. Free Radical Biol. Med., 2007, 42, (2), 260-269
76. Chen, X.L.; Varner, S.E.; Rao, A.S.; Grey, J.Y.; Thomas, S.; Cook, C.K.; Wasserman, M.A.; Medford, R.M.; Jaiswal, A.K.; Kunsch, C., Laminar flow induction of antioxidant response elementmediated genes in endothelial cells. A novel anti-inflammatory mechanism. J. Biol. Chem., 2003, 278, (2), 703-711
77. Cai, H.; McNally, J.S.; Weber, M.; Harrison, D.G., Oscillatory shear stress upregulation of endothelial nitric oxide synthase requires intracellular hydrogen peroxide and CaMKII. J. Mol. Cell Cardiol., 2004, 37, (1), 121-125
78. Mann, G.E.; Niehueser-Saran, J.; Watson, A.; Gao, L.; Ishii, T.; de Winter, P.; Siow, R.C., Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Sheng li xue bao: [Acta physiologica Sinica], 2007, 59, (2), 117-127
79. Kadl, A.; Meher, A.K.; Sharma, P.R.; Lee, M.Y.; Doran, A.C.; Johnstone, S.R.; Elliott, M.R.; Gruber, F.; Han, J.; Chen, W.; Kensler, T.; Ravichandran, K.S.; Isakson, B.E.; Wamhoff, B.R.; Leitinger, N., Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circulation Res., 2010, 107, (6), 737-746
80. Howden, R., Nrf2 and cardiovascular defense. Oxid. Med. Cell Longev., 2013, 2013, 104308
81. Sussan, T.E.; Jun, J.; Thimmulappa, R.; Bedja, D.; Antero, M.; Gabrielson, K.L.; Polotsky, V.Y.; Biswal, S., Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PloS one, 2008, 3, (11), e3791
82. Liu, L.; Xu, D.M.; Cheng, Y.Y., Distinct effects of naringenin and hesperetin on nitric oxide production from endothelial cells. J. Agri. Food Chem., 2008, 56, (3), 824-829
83. Kris-Etherton, P.M.; Hecker, K.D.; Bonanome, A.; Coval, S.M.; Binkoski, A.E.; Hilpert, K.F.; Griel, A.E.; Etherton, T.D., Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med., 2002, 113 Suppl 9B, 71S-88S
84. Neuhouser, M.L.; Patterson, R.E.; Thornquist, M.D.; Omenn, G.S.; King, I.B.; Goodman, G.E., Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the betacarotene and retinol efficacy trial (CARET). Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2003, 12, (4), 350-358
85. Kohle, C.; Bock, K.W., Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals in relation to chemoprevention. Biochem. Pharma., 2006, 72, (7), 795-805
86. Akhlaghi, M.; Bandy, B., Mechanisms of flavonoid protection against myocardial ischemia-reperfusion injury. J. Mol. Cell Cardiol., 2009, 46, (3), 309-317
87. Ramos-Gomez, M.; Kwak, M.K.; Dolan, P.M.; Itoh, K.; Yamamoto, M.; Talalay, P.; Kensler, T.W., Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci.USA, 2001, 98, (6), 3410-3415
88. Gao, X.; Dinkova-Kostova, A.T.; Talalay, P., Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. USA, 2001, 98, (26), 15221-15226
89. Sasaki, S.; Tozawa, T.; Van Wagoner, R.M.; Ireland, C.M.; Harper, M.K.; Satoh, T., Strongylophorine-8, a pro-electrophilic compound from the marine sponge Petrosia (Strongylophora) corticata, provides neuroprotection through Nrf2/ARE pathway. Biochem. Biophys. Res. Commun., 2011, 415, (1), 6-10
90. Chen, H.H.; Chen, Y.T.; Huang, Y.W.; Tsai, H.J.; Kuo, C.C., 4- Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stressinduced cell injury via activation of PI3K/AKT signaling. Free Radical Biol. Med., 2012, 52, (6), 1054-1066
91. Yang, Y.C.; Lii, C.K.; Lin, A.H.; Yeh, Y.W.; Yao, H.T.; Li, C.C.; Liu, K.L.; Chen, H.W., Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids butein and phloretin is mediated through the ERK/Nrf2 pathway and protects against oxidative stress. Free Radical Biol. Med., 2011, 51, (11), 2073-2081
92. Dinkova-Kostova, A.T.; Talalay, P., Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol. Nutr. Food Res., 2008, 52 Suppl 1, S128-138
93. Lee, E.; Yin, Z.; Sidoryk-Wegrzynowicz, M.; Jiang, H.; Aschner, M., 15-Deoxy-Delta12,14-prostaglandin J(2) modulates manganese- induced activation of the NF-kappaB, Nrf2, and PI3K pathways in astrocytes. Free Radical Biol. Med., 52, (6), 1067-1074
94. Lee, D.H.; Goldberg, A.L., Selective inhibitors of the proteasomedependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J. Biol. Chem., 1996, 271, (44), 27280-27284
95. Majetschak, M.; Patel, M.B.; Sorell, L.T.; Liotta, C.; Li, S.; Pham, S.M., Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochem. Biophys. Res. Commun., 2008, 365, (4), 882-888
96. Cui, W.; Bai, Y.; Luo, P.; Miao, L.; Cai, L., Preventive and therapeutic effects of MG132 by activating Nrf2-ARE signaling pathway on oxidative stress-induced cardiovascular and renal injury. Oxid. Med. Cell Longev., 2013, 2013, 306073
97. Chin, M.P.; Wrolstad, D.; Bakris, G.L.; Chertow, G.M.; de Zeeuw, D.; Goldsberry, A.; Linde, P.G.; McCullough, P.A.; McMurray, J.J.; Wittes, J.; Meyer, C.J., Risk Factors for Heart Failure in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl. J. Cardiac Fail., 2014
98. Wallerath, T.; Li, H.; Godtel-Ambrust, U.; Schwarz, P.M.; Forstermann, U., A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide: Biol. Chem./Official J. Nitric Oxide Soc., 2005, 12, (2), 97-104
99. Liu, D.; Homan, L.L.; Dillon, J.S., Genistein acutely stimulates nitric oxide synthesis in vascular endothelial cells by a cyclic adenosine 5'-monophosphate-dependent mechanism. Endocrinology, 2004, 145, (12), 5532-5539
100. Bianco, N.R.; Chaplin, L.J.; Montano, M.M., Differential induction of quinone reductase by phytoestrogens and protection against oestrogen- induced DNA damage. Biochem. J., 2005, 385, (Pt 1), 279-287
101. Strehlow, K.; Rotter, S.; Wassmann, S.; Adam, O.; Grohe, C.; Laufs, K.; Bohm, M.; Nickenig, G., Modulation of antioxidant enzyme expression and function by estrogen. Circulation Res., 2003, 93, (2), 170-177
102. Magesh, S.; Chen, Y.; Hu, L., Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev., 2012, 32, (4), 687-726
103. Liang, L.; Luo, M.; Fu, Y.; Zu, Y.; Wang, W.; Gu, C.; Zhao, C.; Li, C.; Efferth, T., Cajaninstilbene acid (CSA) exerts cytoprotective effects against oxidative stress through the Nrf2-dependent antioxidant pathway. Toxicol. Lett., 2013, 219, (3), 254-261
104. Zeng, C.; Zhong, P.; Zhao, Y.; Kanchana, K.; Zhang, Y.; Khan, Z.A.; Chakrabarti, S.; Wu, L.; Wang, J.; Liang, G., Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo. J. Mol. Cell Cardiol., 2014, 79C, 1-12
105. Liu, P.L.; Liu, J.T.; Kuo, H.F.; Chong, I.W.; Hsieh, C.C., Epigallocatechin Gallate Attenuates Proliferation and Oxidative Stress in Human Vascular Smooth Muscle Cells Induced by Interleukin- 1beta via Heme Oxygenase-1. Mediators Inflamm., 2014, 2014, 523684
106. Lu, J.M.; Nurko, J.; Weakley, S.M.; Jiang, J.; Kougias, P.; Lin, P.H.; Yao, Q.; Chen, C., Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Med. Sci. Monitor: Int. Med. J. Experimental Clin. Res., 2010, 16, (5), RA93-100
107. Tang, Y.L.; Chan, S.W., A review of the pharmacological effects of piceatannol on cardiovascular diseases. Phytotherapy research: PTR, 2014, 28, (11), 1581-1588
108. Ungvari, Z.; Bagi, Z.; Feher, A.; Recchia, F.A.; Sonntag, W.E.; Pearson, K.; de Cabo, R.; Csiszar, A., Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol., 2010, 299, (1), H18-24
109. Sahu, B.D.; Putcha, U.K.; Kuncha, M.; Rachamalla, S.S.; Sistla, R., Carnosic acid promotes myocardial antioxidant response and prevents isoproterenol-induced myocardial oxidative stress and apoptosis in mice. Mol. Cell Biochem., 2014, 394, (1-2), 163-176
110. Qin, X.; Qiu, C.; Zhao, L., Maslinic acid protects vascular smooth muscle cells from oxidative stress through Akt/Nrf2/HO-1 pathway. Mol. Cell Biochem., 2014, 390, (1-2), 61-67
111. Kang, K.A.; Lee, K.H.; Park, J.W.; Lee, N.H.; Na, H.K.; Surh, Y.J.; You, H.J.; Chung, M.H.; Hyun, J.W., Triphlorethol-A induces heme oxygenase-1 via activation of ERK and NF-E2 related factor 2 transcription factor. FEBS lett., 2007, 581, (10), 2000-2008
112. Zhang, H.S.; Wang, S.Q., Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochem. Pharmacol., 2007, 73, (9), 1358-1366
113. Checker, R.; Patwardhan, R.S.; Sharma, D.; Menon, J.; Thoh, M.; Bhilwade, H.N.; Konishi, T.; Sandur, S.K., Schisandrin B exhibits anti-inflammatory activity through modulation of the redoxsensitive transcription factors Nrf2 and NF-kappaB. Free Radical Biol. Med., 2012, 53, (7), 1421-1430
114. Deng, C.; Sun, Z.; Tong, G.; Yi, W.; Ma, L.; Zhao, B.; Cheng, L.; Zhang, J.; Cao, F.; Yi, D., alpha-Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/ reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. PloS one, 2013, 8, (3), e58371
115. Evans, P.C., The influence of sulforaphane on vascular health and its relevance to nutritional approaches to prevent cardiovascular disease. EPMA j., 2011, 2, (1), 9-14
116. Zhu, H.; Itoh, K.; Yamamoto, M.; Zweier, J.L.; Li, Y., Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: protection against reactive oxygen and nitrogen species-induced cell injury. FEBS lett., 2005, 579, (14), 3029-3036
117. Klotz, L.O.; Hou, X.; Jacob, C., 1,4-naphthoquinones: from oxidative damage to cellular and inter-cellular signaling. Molecules, 2014, 19, (9), 14902-14918
118. Wang, Y.K.; Hong, Y.J.; Yao, Y.H.; Huang, X.M.; Liu, X.B.; Zhang, C.Y.; Zhang, L.; Xu, X.L., 6-Shogaol Protects against Oxidized LDL-Induced Endothelial Injruries by Inhibiting Oxidized LDL-Evoked LOX-1 Signaling. Evid. Based Complement. Alternat. Med.: eCAM, 2013, 2013, 503521
119. Bak, M.J.; Ok, S.; Jun, M.; Jeong, W.S., 6-shogaol-rich extract from ginger up-regulates the antioxidant defense systems in cells and mice. Molecules, 2012, 17, (7), 8037-8055
120. Gao, A.M.; Ke, Z.P.; Wang, J.N.; Yang, J.Y.; Chen, S.Y.; Chen, H., Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis, 2013, 34, (8), 1806-1814
121. Tarumoto, T.; Nagai, T.; Ohmine, K.; Miyoshi, T.; Nakamura, M.; Kondo, T.; Mitsugi, K.; Nakano, S.; Muroi, K.; Komatsu, N.; Ozawa, K., Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinibresistant cell line. Experimental Hematol., 2004, 32, (4), 375-381
122. Wang, X.J.; Hayes, J.D.; Henderson, C.J.; Wolf, C.R., Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc. Natl. Acad. Sci. USA, 2007, 104, (49), 19589-19594
123. Ren, D.; Villeneuve, N.F.; Jiang, T.; Wu, T.; Lau, A.; Toppin, H.A.; Zhang, D.D., Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. USA, 2011, 108, (4), 1433-1438
124. Tang, X.; Wang, H.; Fan, L.; Wu, X.; Xin, A.; Ren, H.; Wang, X.J., Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radical Biol. Med., 2011, 50, (11), 1599-1609
125. Boesch-Saadatmandi, C.; Wagner, A.E.; Graeser, A.C.; Hundhausen, C.; Wolffram, S.; Rimbach, G., Ochratoxin A impairs Nrf2-dependent gene expression in porcine kidney tubulus cells. J. Anim. Physiol. Anim. Nutr., 2009, 93, (5), 547-554
126. Arlt, A.; Sebens, S.; Krebs, S.; Geismann, C.; Grossmann, M.; Kruse, M.L.; Schreiber, S.; Schafer, H., Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene, 2013, 32, (40), 4825-4835
127. Autrup, H., Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutation Res., 2000, 464, (1), 65-76
128. Turkanoglu, A.; Can Demirdogen, B.; Demirkaya, S.; Bek, S.; Adali, O., Association analysis of GSTT1, GSTM1 genotype polymorphisms and serum total GST activity with ischemic stroke risk. Neurol. Sci.: Official J. Italian Neurol. Soc. Italian Soc. Clin. Neurophysiol., 2010, 31, (6), 727-734
129. Maciel, S.S.; Pereira Ada, C.; Silva, G.J.; Rodrigues, M.V.; Mill, J.G.; Krieger, J.E., Association between glutathione S-transferase polymorphisms and triglycerides and HDL-cholesterol. Atherosclerosis, 2009, 206, (1), 204-208
130. Ramprasath, T.; Senthil Murugan, P.; Prabakaran, A.D.; Gomathi, P.; Rathinavel, A.; Selvam, G.S., Potential risk modifications of GSTT1, GSTM1 and GSTP1 (glutathione-S-transferases) variants and their association to CAD in patients with type-2 diabetes. Biochem. Biophys. Res. Commun., 2011, 407, (1), 49-53
131. Miller, E.A.; Pankow, J.S.; Millikan, R.C.; Bray, M.S.; Ballantyne, C.M.; Bell, D.A.; Heiss, G.; Li, R., Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis, 2003, 171, (2), 265-272
132. Kucukgergin, C.; Gokpinar, M.; Sanli, O.; Tefik, T.; Oktar, T.; Seckin, S., Association between genetic variants in glutathione peroxidase 1 (GPx1) gene, GPx activity and the risk of prostate cancer. Minerva. Urol. Nefrol. = The Italian journal of urology and nephrology, 2011, 63, (3), 183-190
133. Nemoto, M.; Nishimura, R.; Sasaki, T.; Hiki, Y.; Miyashita, Y.; Nishioka, M.; Fujimoto, K.; Sakuma, T.; Ohashi, T.; Fukuda, K.; Eto, Y.; Tajima, N., Genetic association of glutathione peroxidase- 1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. Cardiovascular diabetology, 2007, 6, 23
134. Tang, N.P.; Wang, L.S.; Yang, L.; Gu, H.J.; Sun, Q.M.; Cong, R.H.; Zhou, B.; Zhu, H.J.; Wang, B., Genetic variant in glutathione peroxidase 1 gene is associated with an increased risk of coronary artery disease in a Chinese population. Clin. Chim. Acta.; Int. J. Clin. Chem., 2008, 395, (1-2), 89-93
135. Lei, C.; Niu, X.; Wei, J.; Zhu, J.; Zhu, Y., Interaction of glutathione peroxidase-1 and selenium in endemic dilated cardiomyopathy. Clin. Chim. Acta.; Int. J. Clin. Chem., 2009, 399, (1-2), 102-108
136. Martin, N.J.; Collier, A.C.; Bowen, L.D.; Pritsos, K.L.; Goodrich, G.G.; Arger, K.; Cutter, G.; Pritsos, C.A., Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. Mutation Res., 2009, 674, (1-2), 93-100
137. Marsden, P.A.; Heng, H.H.; Scherer, S.W.; Stewart, R.J.; Hall, A.V.; Shi, X.M.; Tsui, L.C.; Schappert, K.T., Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem., 1993, 268, (23), 17478-17488
138. Cam, S.F.; Sekuri, C.; Tengiz, I.; Ercan, E.; Sagcan, A.; Akin, M.; Berdeli, A., The G894T polymorphism on endothelial nitric oxide synthase gene is associated with premature coronary artery disease in a Turkish population. Thrombosis Res., 2005, 116, (4), 287-292
139. Nakayama, M.; Yasue, H.; Yoshimura, M.; Shimasaki, Y.; Kugiyama, K.; Ogawa, H.; Motoyama, T.; Saito, Y.; Ogawa, Y.; Miyamoto, Y.; Nakao, K., T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation, 1999, 99, (22), 2864-2870
140. Gardemann, A.; Lohre, J.; Cayci, S.; Katz, N.; Tillmanns, H.; Haberbosch, W., The T allele of the missense Glu(298)Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. Atherosclerosis, 2002, 160, (1), 167-175
141. Chang, K.; Baek, S.H.; Seung, K.B.; Kim, P.J.; Ihm, S.H.; Chae, J.S.; Kim, J.H.; Hong, S.J.; Choi, K.B., The Glu298Asp polymorphism in the endothelial nitric oxide synthase gene is strongly associated with coronary spasm. Coronary Artery Dis., 2003, 14, (4), 293-299.